Butane-1,2,3,4-tetracarboxylic acid

Endpoint summary

Key value for chemical safety assessment

Effects on fertility

Description of key information

The reproductive toxicity study  NOAEL considered to be 500  mg/kg/day,When CD rats were treated with 1,2,3,4-butanetetracarboxylic acid (BTCA) orally.

Link to relevant study records

Reference

Endpoint:

screening for reproductive / developmental toxicity

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

data from handbook or collection of data

Justification for type of information:

Data from peer reviewed journal

Qualifier:

equivalent or similar to guideline

Guideline:

other: under a protocol approved by the RTI Institutional Animal Care and Use Committee (IACUC)

Principles of method if other than guideline:

Reproductive and developmental toxicity study of 1,2,3,4 butane tetra carboxylic acid was performed on Sprague Dawley (CD®) rats

GLP compliance:

not specified

Limit test:

yes

Specific details on test material used for the study:

- Name of the test chemical: Butane-1,2,3,4-tetracarboxylic acid- IUPAC name: Butane-1,2,3,4-tetracarboxylic acid - Molecular Formula: C8H10O8- Molecular Weight: 234.159 g/mol- Smile Notation: OC(=O)C[C@H]([C@H](CC(=O)O)C(=O)O)C(=O)O- InChI : 1S/C8H10O8/c9-5(10)1-3(7(13)14)4(8(15)16)2-6(11)12/h3-4H,1-2H2,(H,9,10)(H,11,12)(H,13,14)(H,15,16)/t3-,4+- Substance type: organic

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS Source: Charles River Laboratories, Inc., Raleigh, NCAge at study initiation: (P) x wks; (F1) x wks: (Parent) 8 to 10 weeks old; Weight at study initiation: (P) Males: x-x g; Females: x-x g; (F1) Males: x-x g; Females: x-x g: Females (P)- 218 to 269 gFasting period before study:Housing:solid bottom, polycarbonate cages with stainless steel lidsUse of restrainers for preventing ingestion (if dermal): yes/no: No Diet (e.g. ad libitum): Purina Certified Rodent Chow, ad libitumWater (e.g. ad libitum): Durham, NC city water, ad libitumAcclimation period: 5 days quarantineENVIRONMENTAL CONDITIONSTemperature (°C): 70 to 73°FHumidity (%): 39 to 60%Air changes (per hr): Photoperiod (hrs dark / hrs light): 12 h light, 12 h darkIN-LIFE DATES: From: To: from gd 0 to gd 20

Route of administration:

oral: gavage

Vehicle:

water

Details on exposure:

Details on exposurePREPARATION OF DOSING SOLUTIONS:DIET PREPARATION- Rate of preparation of diet (frequency):No data available- Mixing appropriate amounts with (Type of food): No data available- Storage temperature of food: No data availableVEHICLE- Justification for use and choice of vehicle (if other than water):- Concentration in vehicle: 0, 250, 500, and 1000 mg/kg/day- Amount of vehicle (if gavage): 5 ml/kg- Lot/batch no. (if required): No data available- Purity: >99%

Details on mating procedure:

- M/F ratio per cage:1:1- Length of cohabitation:After quarantine individual females were placed overnight in the home cage of a singly housed male of the same stock for mating- Proof of pregnancy: [vaginal plug / sperm in vaginal smear] referred to as [day 0 / day 1] of pregnancy:presence of sperm in the vaginal lavage- After ... days of unsuccessful pairing replacement of first male by another male with proven fertility.:No data available- Further matings after two unsuccessful attempts: [no / yes (explain)]:No data available- After successful mating each pregnant female was caged (how):No data available- Any other deviations from standard protocol:No data available

Analytical verification of doses or concentrations:

yes

Details on analytical verification of doses or concentrations:

Dosing solutions (BTCA in deionized/distilled water) were verified to be within 92 to 103% of their theoretical concentrations by HPLC prior to and after the period of administration

Duration of treatment / exposure:

14 days (Gd 6 to Gd 20)

Frequency of treatment:

Gd 0, 6, 9, 12, 15, 18, 19, and 20.

Details on study schedule:

No data available

Remarks:

0,250,500,1000 mg/kg/day

No. of animals per sex per dose:

Total:1000.00mg/kg/day :25250.00mg/kg/day:25500.00mg/kg/day:251000.00mg/kg/day:25

Control animals:

yes, concurrent vehicle

Positive control:

No data available

Parental animals: Observations and examinations:

Parental animals observation and examinationsCAGE SIDE OBSERVATIONS: Yes / No / No data: Not performedDETAILED CLINICAL OBSERVATIONS: Yes / No / No data: YesTime schedule: gd 0, 6, 9, 12, 15, 18, 19, and 20.BODY WEIGHT: Yes / No / No data: YesTime schedule for examinations: gd 0, 6, 9, 12, 15, 18, 19, and 20.FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): YesFood consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes / No / No data: No data availableCompound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes / No / No data: No data availableWATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes / No / No data: YesTime schedule for examinations: gd 0, 6, 9, 12, 15, 18, 19, and 20.

Oestrous cyclicity (parental animals):

No data available

Sperm parameters (parental animals):

No data available

Litter observations:

Each anesthetized fetus was counted, weighed, and examined for external morphologic abnormalities, including cleft palate Approximately one-half (50%) of the anesthetized fetuses were terminated by decapitation and the remaining anesthetizedfetuses by evisceration

Postmortem examinations (parental animals):

SACRIFICEMale animals: All surviving animals [describe when, e.g. as soon as possible after the last litters in each generation were produced.]: No dataMaternal animals: yes All surviving animals [describe when, e.g. after the last litter of each generation was weaned.]: Following termination by CO2 asphyxiation on gd 20,GROSS NECROPSYMaternal liver weight and gravid uterine weight were measured and corpora lutea were counted. Uterine contents were evaluated for the number of implantation sites, resorptions, late fetal deaths (i.e. fetuses with discernible digits and weighing greater than 0.9 g, but displaying no vital signs at the time of uterine dissection), and live fetuses. The uterus was stained to reveal possible early resorptions

Postmortem examinations (offspring):

No data available

Statistics:

The unit for statistical measurement was the pregnant female or the litter. Quantitative continuous data were compared among treatment groups by parametric tests if Bartlett’s test for homogeneity of variance was not significant. If Bartlett’s test indicated a lack of homogeneity (p , 0.001), then nonparametric tests were applied. Statistical analyses were based on SAS software. General Linear Models (GLM) were applied to the Analyses of Variance (ANOVA) and the Tests for Linear Trend. Prior to GLM analysis, an arcsine-square root transformation was performed on all litter-derived percentage data.For litter-derived percentage data, the ANOVA was weighted according to litter size. If a significant (p , 0.05) main effect for dose occurred, then Dunnett’s Multiple Comparison Test was used to compare each treatment group to the control group for that measure. A two-tailed Dunnett’s Test was used for maternal body and organ weight parameters, maternal feed and water consumption, fetal body weight, and percent male fetuses per litter.

Reproductive indices:

No data available

Offspring viability indices:

No data available

Clinical signs:

effects observed, treatment-related

Dermal irritation (if dermal study):

not specified

Mortality:

not specified

Body weight and weight changes:

not specified

Food consumption and compound intake (if feeding study):

not specified

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

not specified

Haematological findings:

not specified

Clinical biochemistry findings:

not specified

Urinalysis findings:

not specified

Behaviour (functional findings):

not specified

Immunological findings:

not specified

Organ weight findings including organ / body weight ratios:

not specified

Histopathological findings: non-neoplastic:

not examined

Histopathological findings: neoplastic:

not specified

Other effects:

not specified

Reproductive function: oestrous cycle:

not specified

Reproductive function: sperm measures:

not specified

Reproductive performance:

not specified

Clinical signs:Treatment-related clinical signs included weight loss (≤5 g in any one weigh period), which occurred occasionally in all groups and showed increasing frequency and/or severity with increasing dose on individual days during the treatment period). Piloerection was noted in ≤4 females/day at the high dose. Rooting in the cage bedding after dosing suggested an aversion to the sensory properties of the mid- and high-dose formulations (≤3 mid-dose females/day and ≤5 high-dose females/day). Alopecia was noted with a low incidence in all groups but showed no apparent relationship to BTCA exposureBody weight and food consumption:Maternal body weight was comparable among groups on gd 0 and 6 (i.e. prior to the initiation of dosing). On gd 9, 12, 15, 18, and 19, maternal body weights at the low and mid doses were not affected (98.8 to 100.8% of concurrent controls), but maternal body weight at the high dose was significantly lower than the vehicle control on each of these days, except gd 9. On gd 20, maternal body weight at the high dose was significantly below the vehicle control. Decreases in maternal body weight became larger with repeated dosing, and the maximum reductions occurred at the end of the dosing period (gd 18, 19, and 20Test substance intake:Maternal relative feed intake was transiently reduced at 1000 mg/kg/day from gd 6 to 9 and at 500 mg/kg/day from gd 12 to 15, although no changes were noted for the treatment period as a whole. Maternal relative water intake was increased at 1000 mg/kg/day for gd 12 to 15, 18 to 19, 19 to 20, and the treatment period as a whole.Reproductive function: estrous cycle:No data availableReproductive function: sperm measures:No data availableReproductive performance:Treatment-related maternal mortality occurred in 4% (1/24) of high-dose females. All remaining females survived until scheduled necropsy on gd 20; pregnancy was confirmed in 84 to 100% per groupOrgan weights:Gravid uterine weight and maternal relative liver weight were not affected. Absolute maternal liver weight exhibited a decreasing trend but showed no significant differences between control and BTCA-treated groups Gross pathology:No data availableHistopathology:No data availableother findings:No data available

Dose descriptor:

NOAEL

Effect level:

500 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

female

Basis for effect level:

body weight and weight gain

food consumption and compound intake

haematology

Remarks on result:

other: not specified

Clinical signs:

not specified

Dermal irritation (if dermal study):

not specified

Mortality:

not specified

Body weight and weight changes:

effects observed, non-treatment-related

Food consumption and compound intake (if feeding study):

not specified

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

not specified

Haematological findings:

not specified

Clinical biochemistry findings:

not specified

Urinalysis findings:

not specified

Behaviour (functional findings):

not specified

Immunological findings:

not specified

Organ weight findings including organ / body weight ratios:

not specified

Gross pathological findings:

not specified

Neuropathological findings:

not specified

Histopathological findings: non-neoplastic:

not specified

Histopathological findings: neoplastic:

not specified

Other effects:

not specified

Reproductive function: oestrous cycle:

not specified

Reproductive function: sperm measures:

not specified

Reproductive performance:

not specified

Clinical signs:

not specified

Dermal irritation (if dermal study):

not specified

Mortality / viability:

not specified

Body weight and weight changes:

not specified

Food consumption and compound intake (if feeding study):

not specified

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

not specified

Haematological findings:

not specified

Clinical biochemistry findings:

not specified

Urinalysis findings:

not specified

Sexual maturation:

not specified

Organ weight findings including organ / body weight ratios:

not specified

Gross pathological findings:

not specified

Histopathological findings:

not specified

Other effects:

not specified

Behaviour (functional findings):

not specified

Developmental immunotoxicity:

not specified

Clinical signs:No data availableBody weight and food consumption:Average fetal body weight per litter in BTCA-treated groups was comparable to controls (97 to 103% of the average control weight for males, females or both sexes combined), and no significant dose-related trends were found. Test substance intake:No data availableReproductive function: estrous cycle:No data availableReproductive function: sperm measures:No data availableReproductive performance:No data availableOrgan weights:No data availableGross pathology:External malformations were limited to one control fetus with a short tail. Visceral malformations included hydronephrosis and/or hydroureter (3, 0, 5, and 1 fetuses in the control through high-dose groups). Each of these visceral findings has a recognizable background incidence in this species/strain and the incidence in this study failed to show a dose-related pattern. Skeletal malformations(fused ribs or centra and split centra) were found in only one fetus in the control group and two fetuses in the Low - dose group. Thus, no association was found between BTCA exposure and the incidence of malformationsHistopathology:No data availableother findings:No data available

Dose descriptor:

other: not specified

Generation:

other: not specified

Based on:

not specified

Sex:

not specified

Basis for effect level:

other: not specified

Remarks on result:

other: not specified

Clinical signs:

not specified

Dermal irritation (if dermal study):

not specified

Mortality / viability:

not specified

Body weight and weight changes:

not specified

Food consumption and compound intake (if feeding study):

not specified

Food efficiency:

not specified

Water consumption and compound intake (if drinking water study):

not specified

Ophthalmological findings:

not specified

Haematological findings:

not specified

Clinical biochemistry findings:

not specified

Urinalysis findings:

not specified

Sexual maturation:

not specified

Organ weight findings including organ / body weight ratios:

not specified

Gross pathological findings:

not specified

Histopathological findings:

not specified

Other effects:

not specified

Behaviour (functional findings):

not specified

Developmental immunotoxicity:

not specified

Reproductive effects observed:

no

Treatment related:

not specified

Relation to other toxic effects:

not specified

Dose response relationship:

not specified

Relevant for humans:

not specified

Conclusions:

The reproductive toxicity study NOAEL considered to be 500 mg/kg/day,When CD rats were treated with 1,2,3,4-butanetetracarboxylic acid (BTCA) orally.

Executive summary:

1,2,3,4-butanetetracarboxylic acid (BTCA) was tested for reproductive toxicity.The experimental animals were Sprague Dawley of 8 to 10 weeks old. After quarantine, individual females were placed overnight in the home cage of a singly housed male of the same stock for mating, and then examined the next morning for the presence of sperm in thevaginal lavage. Female rats weighed from 218 to 269 gon gd 0 (i.e. day of vaginal sperm detection). Time-matedfemales were assigned to treatment groups (25/group) bystratified randomization for body weight on gd 0.

 

The BTCA doses chosen for this study were 0, 250, 500, and 1000 mg/kg/day administered by gavage (5 ml/kg). Dose range selection for this study was based in part on an acute, oral toxicity study of BTCA [800, 1260, 1590, 2000, and 3170 mg/kg] in COX-SD rats. Dose range selection was also supported by a study in non-pregnant female CD rats (7 per group) exposed to BTCA [0, 50,100,500,750, and 1000 mg/kg/day] for 14 consecutive days.

 

Following termination by CO₂asphyxiation on gd 20, maternal liver weight and gravid uterine weight were measured and corpora lutea were counted. Uterine contents were evaluated for the number of implantation sites, resorptions, late fetal deaths (i.e. fetuses with discernible digits and weighing greater than 0.9 g, but displaying no vital signs at the time of uterine dissection), and live fetuses. The uterus was stained to reveal possible early resorptions.

 

Maternal feed and water consumption, body weight, and clinical signs were monitored throughout gestation. At termination (gd 20), confirmed-pregnant females (21 to 25 per group) were evaluated for clinical status and gestational outcome; live fetuses were examined for external, visceral, and skeletal malformations. There were no treatment-related effects on fetal growth, survival, or morphologic development. Therefore NOAEL considered to be 500 mg/kg/day, for the reproductive toxicity study of1, 2,3,4-butanetetracarboxylic acid (BTCA) was performed on CD rats.

 

Effect on fertility: via oral route

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

NOAEL

500 mg/kg bw/day

Study duration:

subacute

Species:

rat

Quality of whole database:

Data is K2 and from peer reviewed journal

Toxicity to reproduction: other studies

Description of key information

Reproductive toxicity

In different studies, 1,2,3,4-butanetetracarboxylic acid (BTCA) (1703-58-8) has been investigated for reproductive toxicity to a greater or lesser extent. Often are the studies based on in vivo experiments and estimated data in rodents, i.e. most commonly in rats for 1,2,3,4-butanetetracarboxylic acid (BTCA) (1703-58-8).

In experimental study given byJulia D. George, Catherine J. Price, Melissa C. Marr, Christina B. Myers,Gloria D. Jahnke(Reproductive Toxicology, 15, (2001), 413–420)1,2,3,4-butanetetracarboxylic acid (BTCA) was tested for reproductive toxicity. The experimental animals were Sprague Dawley of 8 to 10 weeks old. After quarantine, individual females were placed overnight in the home cage of a singly housed male of the same stock for mating, and then examined the next morning for the presence of sperm in the vaginal lavage. Female rats weighed from 218 to 269g on gd 0 (i.e. day of vaginal sperm detection). Time-mated females were assigned to treatment groups (25/group) by stratified randomization for body weight on gd 0.  The BTCA doses chosen for this study were 0, 250, 500, and 1000 mg/kg/day administered by gavage (5 ml/kg). Dose range selection for this study was based in part on an acute, oral toxicity study of BTCA [800, 1260, 1590, 2000, and 3170 mg/kg] in COX-SD rats. Dose range selection was also supported by a study in non-pregnant female CD rats (7 per group) exposed to BTCA [0, 50,100,500,750, and 1000 mg/kg/day] for 14 consecutive days.Following termination by CO2asphyxiation on gd 20, maternal liver weight and gravid uterine weight were measured and corpora lutea were counted. Uterine contents were evaluated for the number of implantation sites, resorptions, late fetal deaths (i.e. fetuses with discernible digits and weighing greater than 0.9 g, but displaying no vital signs at the time of uterine dissection), and live fetuses. The uterus was stained to reveal possible early resorptions.

 Maternal feed and water consumption, body weight, and clinical signs were monitored throughout gestation. At termination (gd 20), confirmed-pregnant females (21 to 25 per group) were evaluated for clinical status and gestational outcome; live fetuses were examined for external, visceral, and skeletal malformations. There were no treatment-related effects on fetal growth, survival, or morphologic development. Therefore NOAEL considered to be 500 mg/kg/day, for the reproductive toxicity study of1, 2,3,4-butanetetracarboxylic acid (BTCA) was performed on CD rats.

 

It is further supported by experimental study given byCatherine J. Price (NTP, TER-97-004, 1998)1,2,3,4-butanetetracarboxylic acid (BTCA) was tested for reproductive toxicity Female Sprague-Dawley-derived (CD®) rats were dosed by gavage with BTCA (0.00, 62.5, 125, 250, 500, or 1000 mg/kg bodyweight/day) or its vehicle (deionized/distilled water) on gd 6 through 19. Fifteen timed-mated females were assigned to each treatment group.At scheduled necropsy, confirmed pregnancy rates were high for all groups (93-100%). For the control through 500 mg/kg/day groups, one female per group was not pregnant. The most frequently observed clinical sign was rooting in the cage bedding after dosing. This behaviour is indicative of an aversion to the taste, odour, or other sensory properties of the dose formulation. Rooting was noted at 500 and 1000 mg/kg/day (maximum incidence of 2 or 10 females per day, respectively). At 2500 mg/kg/day, piloerection was noted in fewer than 10 females/day

Maternal body weight did not differ while average fetal body weight per litter for males (but not females) exhibited a significant decreasing dose-response trend (100, 99, 98, 99, and 94% of the average control weight). Maternal water intake was increased at 1000 mg/kg/day (gd I9 to 20) while food intake was transiently reduced at 1000 mg/kg/day (gd 12 to 15), Gravid uterine weight and maternal absolute liver weight were comparable among groups. Maternal relative liver weight was significantly increased at 250 and 1000 mg/kg/day, but the increase at 500 mg/kg/day failed to reach statistical significance. Prenatal mortality and average live litter size did not differ among groups. No statistically significant differences were observed in the incidence of fetal morphological anomalies (e.g., external malformations or variations). Hence NOAEL considered to be 500 mg/kg/day, in Female Sprague-Dawley-derived (CD®) rats when treated with1,2,3,4-butanetetracarboxylic acid (BTCA) by oral gavage route .

 Also another experimental study given byCatherine J. Price(National Toxicology Program, National Institute of Environmental Health Sciences, 1999)1,2,3,4-butanetetracarboxylic acid (BTCA) was tested for reproductive toxicity. The tests were conducted in accordance with the Food and Drug Administration Good Laboratory Practice Regulations for Nonclinical Laboratory Studies, with the Guide for the Care and Use of Laboratory Animals and under a protocol approved by the RTI Institutional Animal Care and Use Committee (IACUC)

 The experimental animals were CrI:CD®(SD)BRV AF/Plus® outbred albino rats (CD® rats] of 8 to 10 weeks old. After quarantine, individual females were placed overnight in the home cage of a singly housed male of the same stock for mating, and then examined the next morning for the presence of sperm in the vaginal lavage. Female rats weighed from 218 to 269g on gd 0 (i.e. day of vaginal sperm detection). Time-mated females were assigned to treatment groups (25/group) by stratified randomization for body weight on gd 0.

 

The BTCA doses chosen for this study were 0, 250, 500, and 1000 mg/kg/day administered by gavage (5 ml/kg). Dose range selection for this study was based in part on an acute, oral toxicity study of BTCA [800, 1260, 1590, 2000, and 3170 mg/kg] in COX-SD rats. Dose range selection was also supported by a study in nonpregnant female CD rats (7 per group) exposed to BTCA [0,50,100,500,750, and 1000 mg/kg/day] for 14 consecutive days.Following termination by CO2asphyxiation on gd 20, maternal liver weight and gravid uterine weight were measured and corpora lutea were counted. Uterine contents were evaluated for the number of implantation sites, resorptions, late fetal deaths (i.e. fetuses with discernible digits and weighing greater than 0.9 g, but displaying no vital signs at the time of uterine dissection), and live fetuses. The uterus was stained to reveal possible early resorptions.

 Maternal feed and water consumption, body weight, and clinical signs were monitored throughout gestation. At termination (gd 20), confirmed-pregnant females (21 to 25 per group) were evaluated for clinical status and gestational outcome; live fetuses were examined for external, visceral, and skeletal malformations. There were no treatment-related effects on fetal growth, survival, or morphologic development.The maternal toxicity NOAEL considered to be 500 mg/kg/day, when Female Sprague-Dawley-derived (CD®) rats treated with 1,2,3,4-butanetetracarboxylic acid (BTCA) by oral gavage route from gestational day 6 through19.

 

 

It is further supported by experimental study given byLayton K, Wolfe G, Wang Y, Quance J, Bishop J(Toxicologist 2002 Mar;66(1S):233)The 1,2,3,4 butane tetra carboxylic acid was evaluated using the multigenerational Continuous Breeding paradigm to reveal potential reproductive toxicity in Sprague Dawley rats. Beginning on Study Day 1, BTCA was administered daily via oral gavage at doses of 0, 100, 250, 500 mg/kg/day to adult male and female rats (N = 20). Mating pairs were allowed to produce three litters (F1a, F1b, and F1c).Dosing of the F1 generation (F1c animals) was initiated on postnatal day (PND) 22. On PND 81 +/10, F1c (N = 20) animals were assigned to mating pairs and allowed to produce there litters (F2a, F2b, and F2c).

 No changes were seen in the body weights or feed consumption of the F0 animals. Decreases of 45% were seen in the body weights of the 500 mg/kg F1c males during Week 2, and Weeks 12- 16.Feed consumption was decreased during Week 12 for the 100 mg/kg F1c males. Throughout the F0 and F1 generations, most reproductive parameters were unchanged in all dose groups compared to the controls, except decrease in the pregnancy indices in the 500 mg/kg pairs compared to control during the second litter of each generation (F1b: 13/17 compared to 20/20, F2b: 16/20 compared to 20/20).Sperm parameters and vaginal cytology were unchanged in the F0 and F1 generations.The 1,2,3,4 butane tetra carboxylic acid produced no reproductive toxicity. So BTCA would not be considered a reproductive toxicant. Therefore NOAEL for 1,2,3,4 butane tetra carboxylic acid can be considered as 250mg/kg in Sprague Dawley rats by oral gavage route.

 Based on the above study on1,2,3,4 butane tetra carboxylic acid(1703-58-8), it can be concluded that NOAEL value is 500mg/kg bw. Thus, comparing this value with the criteria of CLP regulation,1,2,3,4 butane tetra carboxylic acid(1703-58-8)can be "Not classified" for reproductive toxicity.

 

 

Justification for classification or non-classification

 Based on the above study on1,2,3,4 butane tetra carboxylic acid(1703-58-8), it can be concluded that NOAEL value is 500mg/kg bw. Thus, comparing this value with the criteria of CLP regulation,1,2,3,4 butane tetra carboxylic acid(1703-58-8)can be "Not classified" for reproductive toxicity.